Asthma is a chronic inflammatory disease of the airways characterized by episodes of wheezing, breathlessness, chest tightness and coughing. It affects over 160 million people worldwide. The main goals of long-term asthma management are to achieve and maintain control of symptoms, prevent exacerbations, and avoid adverse effects from medications through a treatment plan tailored to the individual patient's severity level. Proper inhaler technique and medication adherence are critical for effective asthma control.
Bronchial asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness and reversible airflow obstruction. The cardinal symptoms are cough, dyspnea, and wheezing. Triggers include pollens, pets, pollution, pharmacological agents, and repeated respiratory tract infections. Treatment includes bronchodilators like beta-2 agonists for quick symptom relief and corticosteroids as long-term controllers to reduce inflammation and prevent exacerbations. Other treatments target specific mediators like leukotriene antagonists or mast cell stabilizers. Severe refractory asthma may be treated with monoclonal antibody therapy against IgE.
A 19-year old female college student with a history of persistent asthma and allergic rhinitis was admitted to the student health service overnight for increased shortness of breath, wheezing, poor exercise tolerance, and nasal stuffiness. She improved after receiving oxygen, bronchodilators, and corticosteroids. The document discusses asthma pathogenesis, diagnosis, treatment including pharmacotherapy and environmental control, and goals of chronic asthma management.
Asthma is a chronic inflammatory disease of the airways that causes periodic obstruction of airflow. The document outlines the pharmacological basis for treating asthma, including the pathophysiology and various drug classes used. The main drug classes used are bronchodilators like beta-2 agonists, corticosteroids, leukotriene modifiers, and monoclonal antibodies. Treatment is aimed at preventing symptoms, exacerbations, and maintaining normal lung function and activity levels.
This document provides an overview of bronchial asthma. It begins by defining asthma as a chronic inflammatory disease of the airways characterized by reversible episodes of airway obstruction. It then describes the pathophysiology of asthma including the early acute phase involving bronchial smooth muscle spasm and the chronic phase involving ongoing inflammation. It outlines the clinical features of asthma and divides it into extrinsic and intrinsic types. The document thoroughly explains the pathophysiology and treatment approaches for asthma including short acting bronchodilators, long term controllers like corticosteroids, mast cell stabilizers, leukotriene modifiers, monoclonal anti-IgE antibody, and others. It also provides details on drug mechanisms and management of acute severe asthma exacerbations.
This document discusses approaches to asthma and newer modalities in treatment. It begins by defining asthma as a chronic airway inflammation disease characterized by variable respiratory symptoms. It then discusses triggers of asthma attacks and the pathophysiology involving immune cells like mast cells, basophils, and eosinophils. The document outlines the diagnostic approach including assessing symptoms, lung function testing, allergy testing, and trial of treatments. It also discusses managing asthma through a stepwise treatment approach based on symptom severity. Finally, it introduces several newer treatment modalities for asthma including allergen immunotherapy, anti-IgE therapy like Omalizumab, and long-acting bronchodilators.
Drugs of Asthma, Management of status asthmaticusMustafaAhmed251
This document discusses drugs used to treat asthma. It defines asthma as a chronic inflammatory lung disease characterized by episodic attacks of wheezing, shortness of breath, mucus production, and chest tightness, often occurring in early morning or evening. The causes include genetic factors and environmental triggers like allergens, infections, smoking, and stress. The main drug classes used to treat asthma are bronchodilators and anti-inflammatory steroids. Bronchodilators work directly on airway smooth muscle or indirectly and include short-acting beta-2 agonists like salbutamol for emergency use and long-acting ones like salmeterol. Corticosteroids reduce inflammation and are administered intravenously, or
Bronchial asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness and reversible airflow obstruction. The cardinal symptoms are cough, dyspnea, and wheezing. Triggers include pollens, pets, pollution, pharmacological agents, and repeated respiratory tract infections. Treatment includes bronchodilators like beta-2 agonists for quick symptom relief and corticosteroids as long-term controllers to reduce inflammation and prevent exacerbations. Other treatments target specific mediators like leukotriene antagonists or mast cell stabilizers. Severe refractory asthma may be treated with monoclonal antibody therapy against IgE.
A 19-year old female college student with a history of persistent asthma and allergic rhinitis was admitted to the student health service overnight for increased shortness of breath, wheezing, poor exercise tolerance, and nasal stuffiness. She improved after receiving oxygen, bronchodilators, and corticosteroids. The document discusses asthma pathogenesis, diagnosis, treatment including pharmacotherapy and environmental control, and goals of chronic asthma management.
Asthma is a chronic inflammatory disease of the airways that causes periodic obstruction of airflow. The document outlines the pharmacological basis for treating asthma, including the pathophysiology and various drug classes used. The main drug classes used are bronchodilators like beta-2 agonists, corticosteroids, leukotriene modifiers, and monoclonal antibodies. Treatment is aimed at preventing symptoms, exacerbations, and maintaining normal lung function and activity levels.
This document provides an overview of bronchial asthma. It begins by defining asthma as a chronic inflammatory disease of the airways characterized by reversible episodes of airway obstruction. It then describes the pathophysiology of asthma including the early acute phase involving bronchial smooth muscle spasm and the chronic phase involving ongoing inflammation. It outlines the clinical features of asthma and divides it into extrinsic and intrinsic types. The document thoroughly explains the pathophysiology and treatment approaches for asthma including short acting bronchodilators, long term controllers like corticosteroids, mast cell stabilizers, leukotriene modifiers, monoclonal anti-IgE antibody, and others. It also provides details on drug mechanisms and management of acute severe asthma exacerbations.
This document discusses approaches to asthma and newer modalities in treatment. It begins by defining asthma as a chronic airway inflammation disease characterized by variable respiratory symptoms. It then discusses triggers of asthma attacks and the pathophysiology involving immune cells like mast cells, basophils, and eosinophils. The document outlines the diagnostic approach including assessing symptoms, lung function testing, allergy testing, and trial of treatments. It also discusses managing asthma through a stepwise treatment approach based on symptom severity. Finally, it introduces several newer treatment modalities for asthma including allergen immunotherapy, anti-IgE therapy like Omalizumab, and long-acting bronchodilators.
Drugs of Asthma, Management of status asthmaticusMustafaAhmed251
This document discusses drugs used to treat asthma. It defines asthma as a chronic inflammatory lung disease characterized by episodic attacks of wheezing, shortness of breath, mucus production, and chest tightness, often occurring in early morning or evening. The causes include genetic factors and environmental triggers like allergens, infections, smoking, and stress. The main drug classes used to treat asthma are bronchodilators and anti-inflammatory steroids. Bronchodilators work directly on airway smooth muscle or indirectly and include short-acting beta-2 agonists like salbutamol for emergency use and long-acting ones like salmeterol. Corticosteroids reduce inflammation and are administered intravenously, or
This document summarizes drugs that affect the respiratory system, including those used to treat common colds, allergies, asthma, and COPD. It describes the actions, indications, and side effects of various antihistamines, decongestants, expectorants, bronchodilators, corticosteroids, and other drugs. These include diphenhydramine, loratadine, cetirizine, pseudoephedrine, guaifenesin, albuterol, cromolyn, fluticasone, prednisone, ipratropium, salmeterol, and theophylline. Non-pharmacological treatment strategies are also mentioned, such
The document discusses an update on asthma presented by Dr. Joseph A. Aluoch, covering topics such as the heterogeneity of asthma phenotypes, the importance of establishing a diagnosis and differentiating asthma from other conditions, goals of asthma management including improving control and reducing risk of exacerbations, and therapeutic strategies such as patient education.
Bronchial asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness and reversible airway obstruction. It is caused by a complex interaction between genetic and environmental factors that lead to airway inflammation and constriction. The document discusses the definition, pathogenesis, triggers, diagnosis and management of asthma with both short-acting bronchodilators and long-term control medications to reduce inflammation and prevent symptoms.
Pharmacotherapy in bronchial asthma and recent advancesDr Resu Neha Reddy
A 32-year-old female patient presented to the emergency room with acute dyspnea, dry cough, and wheezing. She has a history of recurrent similar attacks that are made worse by exercise and dust exposure. The document provides an overview of bronchial asthma including its history, pathophysiology, triggers, diagnosis, and pharmacotherapy. It discusses the inflammatory process and mediators involved in asthma as well as treatment options like bronchodilators, corticosteroids, leukotriene modifiers, and monoclonal antibodies.
Anaphylaxis is a severe allergic reaction that is potentially life-threatening and must be treated as a medical emergency. Common causes include medications like antibiotics, stings from insects like bees, foods like nuts and shellfish, latex, and exercise. Symptoms can affect the skin, respiratory system, cardiovascular system, abdomen, and other areas. Treatment involves epinephrine injection, antihistamines, corticosteroids, and activating emergency services.
The document summarizes modern trends in the management of bronchial asthma. It discusses how airway inflammation is a critical component of asthma and can be present even without severe symptoms. Current therapy includes bronchodilators and anti-inflammatory drugs like corticosteroids and leukotriene inhibitors. Inhaled corticosteroids and leukotriene inhibitors are the first-line therapy to both prevent and control symptoms. The document also discusses the pathophysiology and histopathology of asthma, as well as various triggers, clinical features, and management approaches.
Bronchial asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, and coughing. The inflammation causes increased airway responsiveness to various stimuli. Asthma is categorized based on frequency and severity of symptoms. The pathophysiology involves genetic predisposition to allergic reactions, airway inflammation, and bronchial hyperresponsiveness triggered by allergens, viruses, pollution, and other factors. Mediators such as leukotrienes and histamine cause bronchospasm. Histological examination shows mucus plugs, eosinophils, and muscle hypertrophy in the airways.
This document discusses the pharmacotherapy of bronchial asthma. It begins by classifying asthma and outlining its pathophysiology. It then describes various routes of drug administration, focusing on inhaled delivery methods like metered dose inhalers and nebulizers. The document details the management of asthma through both non-pharmacological and pharmacological approaches. It provides an overview of the main drug classes used to treat asthma, including beta-2 agonists, anticholinergics, methylxanthines, corticosteroids, and others. For each class, it outlines examples of drugs, their mechanisms of action, uses, dosages, and side effects.
This document provides an overview of bronchial asthma, including its definition, pathophysiology, types, triggers, symptoms, diagnosis, management, and differences from COPD. Key points include:
- Asthma is a disease characterized by reversible airway obstruction and inflammation in response to various stimuli. It is an IgE-mediated hypersensitivity reaction.
- Common symptoms include wheezing, chest tightness, cough and breathlessness. Diagnosis is based on clinical history and pulmonary function tests showing improved airflow with bronchodilators.
- Management involves avoidance of triggers, bronchodilators, inhaled corticosteroids, and a stepped treatment plan escalating medications based on asthma control. Acute
Bronchodilators like short-acting beta-agonists treat acute asthma attacks by relaxing airway smooth muscle. Anti-inflammatory drugs like inhaled corticosteroids and leukotriene receptor antagonists are used for prophylaxis to reduce inflammation and prevent attacks. Inhaled corticosteroids are the most effective anti-inflammatory for long-term asthma control while mast cell stabilizers and leukotriene antagonists are alternatives. Drugs for chronic obstructive pulmonary disease similarly include bronchodilators and may add inhaled corticosteroids.
Reference:
K. D. Tripathi. Essentials of Medical Pharmacology, 6th edition. Jaypee Publication Pg. No. 213-230.
This slide deck give detail presentation on causes, pathophysiology and pharmacotherapy of bronchial asthma.
For all IV video lecture series of this topic click:
https://youtube.com/playlist?list=PLBVbJ9HCa1BYdASIBMWSjjSL7zVHHVW1l
- For More Such Learning You Can Subscribe to My YouTube Channel.
https://www.youtube.com/channel/UC5o-WkzmDJaF7udyAP2jtgw/featured?sub_confirmation=1
Facebook Page: https://www.facebook.com/asacademylearningforever
Website Blog: https://itasacademy.blogspot.com/
This document discusses the pharmacotherapy of bronchial asthma. It begins by defining asthma as a chronic airway inflammatory condition characterized by airflow obstruction and airway hyperresponsiveness. It then discusses the various triggers that can induce asthma symptoms. The key pathological features involve an exaggerated TH2 response leading to eosinophilic inflammation. Treatment aims to both relieve acute attacks with bronchodilators and reduce inflammation with controllers like corticosteroids. The document provides detailed information on the mechanisms and use of various drug classes for asthma treatment including beta-agonists, corticosteroids, leukotriene modifiers, methylxanthines, and others. It also discusses approaches for classifying patients and managing asthma long-term based on control
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and airway hyperresponsiveness. It has different classifications based on severity and is treated through long-term control medications like inhaled corticosteroids and bronchodilators as well as quick-relief medications for acute symptoms. The pathophysiology involves airway inflammation, remodeling, and hyperresponsiveness triggered by allergens, infections, and other environmental factors.
This document summarizes guidelines for managing bronchial asthma, including goals of management, developing patient-doctor relationships, identifying risk factors, assessing and monitoring asthma control, and managing exacerbations. The key aspects are controlling symptoms, maintaining normal activity, preventing exacerbations and mortality, educating patients, identifying triggers, using reliever and controller medications appropriately, and treating exacerbations based on severity.
This document discusses bronchial asthma, including its definition, prevalence, etiology, triggers, pathogenesis, clinical features, classification of severity, diagnosis, investigations, management, pharmacotherapy, acute severe asthma/status asthmaticus, and considerations for dental treatment of asthmatic patients. Key points include that asthma is a chronic inflammatory disease characterized by reversible airway obstruction, it affects over 300 million people worldwide, treatment involves bronchodilators, corticosteroids, leukotriene antagonists and others to control symptoms and exacerbations, and special precautions should be taken when providing dental care to asthmatic patients to prevent triggering an attack.
This patient presents with an acute exacerbation of asthma. She has a history of asthma and is experiencing tachypnea, shortness of breath, wheezing, and her symptoms are not relieved by her usual medications. On examination, she has tachycardia, tachypnea, use of accessory muscles, decreased breath sounds, and wheezing. Her oxygen saturation is low. Treatment should focus on aggressive use of bronchodilators and systemic corticosteroids to reverse the exacerbation. Close monitoring is needed given the severity of the presentation.
Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction. It affects 300 million people worldwide and poses a large socioeconomic burden. The disease severity can range from intermittent to persistent daily symptoms. Common triggers include allergens, infections, pollution, and exercise. Diagnosis involves assessing symptoms, lung function testing, and allergy testing. Treatment involves avoidance of triggers, bronchodilators for relief of acute symptoms, and anti-inflammatory controllers like inhaled corticosteroids to prevent symptoms and exacerbations.
This document provides an overview of bronchial asthma including its definition, history, epidemiology, pathophysiology, diagnosis, classification, treatment and recent advances. It defines bronchial asthma as a chronic inflammatory airway disease causing periodic airway constriction and reversible symptoms. It discusses the epidemiology of asthma globally and risk factors. It covers diagnostic tests, classification of asthma severity, pharmacological treatment including bronchodilators, corticosteroids, leukotriene antagonists and recent drugs.
Allergens from dust mites, pollen, and other irritants can trigger allergies and asthma attacks by causing symptoms like sneezing, wheezing, and difficulty breathing during exercise. Chemical pollutants from smokestacks and the environment can also irritate the lungs and worsen asthma. The author learned that common indoor allergens like dust mites and cockroaches live in carpets and rugs and cause allergies, and that exercise and chemicals in smoke can make breathing difficult for people and animals with asthma.
1. Asthma is a chronic inflammatory disorder of the airways that affects 15-20 million people in India. It is characterized by airway hyperresponsiveness and inflammation.
2. Proper diagnosis involves assessing patient history of symptoms, performing a physical exam, and measuring lung function through methods like peak flow meters. Treatment involves a stepwise approach using reliever and preventer medications.
3. Relievers provide quick symptom relief but are not for regular use. Preventers help control inflammation and symptoms over the long-term and include inhaled corticosteroids, long-acting beta-agonists, and other drugs. Combination inhalers containing both a preventer and reliever are often ideal
This document summarizes drugs that affect the respiratory system, including those used to treat common colds, allergies, asthma, and COPD. It describes the actions, indications, and side effects of various antihistamines, decongestants, expectorants, bronchodilators, corticosteroids, and other drugs. These include diphenhydramine, loratadine, cetirizine, pseudoephedrine, guaifenesin, albuterol, cromolyn, fluticasone, prednisone, ipratropium, salmeterol, and theophylline. Non-pharmacological treatment strategies are also mentioned, such
The document discusses an update on asthma presented by Dr. Joseph A. Aluoch, covering topics such as the heterogeneity of asthma phenotypes, the importance of establishing a diagnosis and differentiating asthma from other conditions, goals of asthma management including improving control and reducing risk of exacerbations, and therapeutic strategies such as patient education.
Bronchial asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness and reversible airway obstruction. It is caused by a complex interaction between genetic and environmental factors that lead to airway inflammation and constriction. The document discusses the definition, pathogenesis, triggers, diagnosis and management of asthma with both short-acting bronchodilators and long-term control medications to reduce inflammation and prevent symptoms.
Pharmacotherapy in bronchial asthma and recent advancesDr Resu Neha Reddy
A 32-year-old female patient presented to the emergency room with acute dyspnea, dry cough, and wheezing. She has a history of recurrent similar attacks that are made worse by exercise and dust exposure. The document provides an overview of bronchial asthma including its history, pathophysiology, triggers, diagnosis, and pharmacotherapy. It discusses the inflammatory process and mediators involved in asthma as well as treatment options like bronchodilators, corticosteroids, leukotriene modifiers, and monoclonal antibodies.
Anaphylaxis is a severe allergic reaction that is potentially life-threatening and must be treated as a medical emergency. Common causes include medications like antibiotics, stings from insects like bees, foods like nuts and shellfish, latex, and exercise. Symptoms can affect the skin, respiratory system, cardiovascular system, abdomen, and other areas. Treatment involves epinephrine injection, antihistamines, corticosteroids, and activating emergency services.
The document summarizes modern trends in the management of bronchial asthma. It discusses how airway inflammation is a critical component of asthma and can be present even without severe symptoms. Current therapy includes bronchodilators and anti-inflammatory drugs like corticosteroids and leukotriene inhibitors. Inhaled corticosteroids and leukotriene inhibitors are the first-line therapy to both prevent and control symptoms. The document also discusses the pathophysiology and histopathology of asthma, as well as various triggers, clinical features, and management approaches.
Bronchial asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, and coughing. The inflammation causes increased airway responsiveness to various stimuli. Asthma is categorized based on frequency and severity of symptoms. The pathophysiology involves genetic predisposition to allergic reactions, airway inflammation, and bronchial hyperresponsiveness triggered by allergens, viruses, pollution, and other factors. Mediators such as leukotrienes and histamine cause bronchospasm. Histological examination shows mucus plugs, eosinophils, and muscle hypertrophy in the airways.
This document discusses the pharmacotherapy of bronchial asthma. It begins by classifying asthma and outlining its pathophysiology. It then describes various routes of drug administration, focusing on inhaled delivery methods like metered dose inhalers and nebulizers. The document details the management of asthma through both non-pharmacological and pharmacological approaches. It provides an overview of the main drug classes used to treat asthma, including beta-2 agonists, anticholinergics, methylxanthines, corticosteroids, and others. For each class, it outlines examples of drugs, their mechanisms of action, uses, dosages, and side effects.
This document provides an overview of bronchial asthma, including its definition, pathophysiology, types, triggers, symptoms, diagnosis, management, and differences from COPD. Key points include:
- Asthma is a disease characterized by reversible airway obstruction and inflammation in response to various stimuli. It is an IgE-mediated hypersensitivity reaction.
- Common symptoms include wheezing, chest tightness, cough and breathlessness. Diagnosis is based on clinical history and pulmonary function tests showing improved airflow with bronchodilators.
- Management involves avoidance of triggers, bronchodilators, inhaled corticosteroids, and a stepped treatment plan escalating medications based on asthma control. Acute
Bronchodilators like short-acting beta-agonists treat acute asthma attacks by relaxing airway smooth muscle. Anti-inflammatory drugs like inhaled corticosteroids and leukotriene receptor antagonists are used for prophylaxis to reduce inflammation and prevent attacks. Inhaled corticosteroids are the most effective anti-inflammatory for long-term asthma control while mast cell stabilizers and leukotriene antagonists are alternatives. Drugs for chronic obstructive pulmonary disease similarly include bronchodilators and may add inhaled corticosteroids.
Reference:
K. D. Tripathi. Essentials of Medical Pharmacology, 6th edition. Jaypee Publication Pg. No. 213-230.
This slide deck give detail presentation on causes, pathophysiology and pharmacotherapy of bronchial asthma.
For all IV video lecture series of this topic click:
https://youtube.com/playlist?list=PLBVbJ9HCa1BYdASIBMWSjjSL7zVHHVW1l
- For More Such Learning You Can Subscribe to My YouTube Channel.
https://www.youtube.com/channel/UC5o-WkzmDJaF7udyAP2jtgw/featured?sub_confirmation=1
Facebook Page: https://www.facebook.com/asacademylearningforever
Website Blog: https://itasacademy.blogspot.com/
This document discusses the pharmacotherapy of bronchial asthma. It begins by defining asthma as a chronic airway inflammatory condition characterized by airflow obstruction and airway hyperresponsiveness. It then discusses the various triggers that can induce asthma symptoms. The key pathological features involve an exaggerated TH2 response leading to eosinophilic inflammation. Treatment aims to both relieve acute attacks with bronchodilators and reduce inflammation with controllers like corticosteroids. The document provides detailed information on the mechanisms and use of various drug classes for asthma treatment including beta-agonists, corticosteroids, leukotriene modifiers, methylxanthines, and others. It also discusses approaches for classifying patients and managing asthma long-term based on control
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and airway hyperresponsiveness. It has different classifications based on severity and is treated through long-term control medications like inhaled corticosteroids and bronchodilators as well as quick-relief medications for acute symptoms. The pathophysiology involves airway inflammation, remodeling, and hyperresponsiveness triggered by allergens, infections, and other environmental factors.
This document summarizes guidelines for managing bronchial asthma, including goals of management, developing patient-doctor relationships, identifying risk factors, assessing and monitoring asthma control, and managing exacerbations. The key aspects are controlling symptoms, maintaining normal activity, preventing exacerbations and mortality, educating patients, identifying triggers, using reliever and controller medications appropriately, and treating exacerbations based on severity.
This document discusses bronchial asthma, including its definition, prevalence, etiology, triggers, pathogenesis, clinical features, classification of severity, diagnosis, investigations, management, pharmacotherapy, acute severe asthma/status asthmaticus, and considerations for dental treatment of asthmatic patients. Key points include that asthma is a chronic inflammatory disease characterized by reversible airway obstruction, it affects over 300 million people worldwide, treatment involves bronchodilators, corticosteroids, leukotriene antagonists and others to control symptoms and exacerbations, and special precautions should be taken when providing dental care to asthmatic patients to prevent triggering an attack.
This patient presents with an acute exacerbation of asthma. She has a history of asthma and is experiencing tachypnea, shortness of breath, wheezing, and her symptoms are not relieved by her usual medications. On examination, she has tachycardia, tachypnea, use of accessory muscles, decreased breath sounds, and wheezing. Her oxygen saturation is low. Treatment should focus on aggressive use of bronchodilators and systemic corticosteroids to reverse the exacerbation. Close monitoring is needed given the severity of the presentation.
Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction. It affects 300 million people worldwide and poses a large socioeconomic burden. The disease severity can range from intermittent to persistent daily symptoms. Common triggers include allergens, infections, pollution, and exercise. Diagnosis involves assessing symptoms, lung function testing, and allergy testing. Treatment involves avoidance of triggers, bronchodilators for relief of acute symptoms, and anti-inflammatory controllers like inhaled corticosteroids to prevent symptoms and exacerbations.
This document provides an overview of bronchial asthma including its definition, history, epidemiology, pathophysiology, diagnosis, classification, treatment and recent advances. It defines bronchial asthma as a chronic inflammatory airway disease causing periodic airway constriction and reversible symptoms. It discusses the epidemiology of asthma globally and risk factors. It covers diagnostic tests, classification of asthma severity, pharmacological treatment including bronchodilators, corticosteroids, leukotriene antagonists and recent drugs.
Allergens from dust mites, pollen, and other irritants can trigger allergies and asthma attacks by causing symptoms like sneezing, wheezing, and difficulty breathing during exercise. Chemical pollutants from smokestacks and the environment can also irritate the lungs and worsen asthma. The author learned that common indoor allergens like dust mites and cockroaches live in carpets and rugs and cause allergies, and that exercise and chemicals in smoke can make breathing difficult for people and animals with asthma.
1. Asthma is a chronic inflammatory disorder of the airways that affects 15-20 million people in India. It is characterized by airway hyperresponsiveness and inflammation.
2. Proper diagnosis involves assessing patient history of symptoms, performing a physical exam, and measuring lung function through methods like peak flow meters. Treatment involves a stepwise approach using reliever and preventer medications.
3. Relievers provide quick symptom relief but are not for regular use. Preventers help control inflammation and symptoms over the long-term and include inhaled corticosteroids, long-acting beta-agonists, and other drugs. Combination inhalers containing both a preventer and reliever are often ideal
Lightning Talk #9: How UX and Data Storytelling Can Shape Policy by Mika Aldabaux singapore
How can we take UX and Data Storytelling out of the tech context and use them to change the way government behaves?
Showcasing the truth is the highest goal of data storytelling. Because the design of a chart can affect the interpretation of data in a major way, one must wield visual tools with care and deliberation. Using quantitative facts to evoke an emotional response is best achieved with the combination of UX and data storytelling.
http://inarocket.com
Learn BEM fundamentals as fast as possible. What is BEM (Block, element, modifier), BEM syntax, how it works with a real example, etc.
The document discusses how personalization and dynamic content are becoming increasingly important on websites. It notes that 52% of marketers see content personalization as critical and 75% of consumers like it when brands personalize their content. However, personalization can create issues for search engine optimization as dynamic URLs and content are more difficult for search engines to index than static pages. The document provides tips for SEOs to help address these personalization and SEO challenges, such as using static URLs when possible and submitting accurate sitemaps.
This document summarizes a study of CEO succession events among the largest 100 U.S. corporations between 2005-2015. The study analyzed executives who were passed over for the CEO role ("succession losers") and their subsequent careers. It found that 74% of passed over executives left their companies, with 30% eventually becoming CEOs elsewhere. However, companies led by succession losers saw average stock price declines of 13% over 3 years, compared to gains for companies whose CEO selections remained unchanged. The findings suggest that boards generally identify the most qualified CEO candidates, though differences between internal and external hires complicate comparisons.
How to Build a Dynamic Social Media PlanPost Planner
Stop guessing and wasting your time on networks and strategies that don’t work!
Join Rebekah Radice and Katie Lance to learn how to optimize your social networks, the best kept secrets for hot content, top time management tools, and much more!
Watch the replay here: bit.ly/socialmedia-plan
5. Bronchial asthma treatment and prognosis .pdfShinilLenin
This document provides an overview of bronchial asthma including its pathophysiology, causes, diagnosis, and management. It defines asthma as a chronic inflammatory airway disease characterized by recurrent episodes of wheezing, breathlessness, and coughing. Environmental factors and genetic susceptibility contribute to its development. Spirometry is important for diagnosis and monitoring treatment. Management involves both controller medications like inhaled corticosteroids to reduce inflammation and reliever medications like short-acting beta
Bronchial Asthma - Epidemiology, Pathogenesis and ManagementShashikiran Umakanth
Bronchial asthma is a chronic disease with airway inflammation as a central theme in its pathogenesis. Prevalence of this condition is gradually increasing, especially in developed countries and in countries that are getting "westernized". With early diagnosis, regular monitoring and prompt and rational treatment, most patients with asthma can lead a symptom-free life.
This document defines bronchial asthma and discusses its epidemiology, etiology, pathology, clinical features, diagnosis, classification of severity, and treatment. Some key points:
- Asthma is a chronic inflammatory disorder characterized by airway hyperresponsiveness leading to reversible airflow obstruction. It affects 300 million people globally.
- Both genetic and environmental factors contribute to asthma development, including atopy, air pollution, allergens, and occupational sensitizers.
- Pathologically, it involves eosinophilic inflammation and thickening of the airway walls. Clinically, it presents with wheezing, coughing, and shortness of breath.
- Diagnosis involves lung function tests showing reversibility and
Asthma attack(status asthmaticus) Groups Mzhda Salman
This document provides an overview of asthma, including:
1) Asthma is a chronic inflammatory disease of the airways characterized by recurrent wheezing, chest tightness, coughing, and shortness of breath.
2) Risk factors include genetic and environmental factors such as exposure to allergens, tobacco smoke, and viral infections.
3) Diagnosis is based on a patient's respiratory symptoms and improvement following bronchodilator treatment; spirometry can also be used.
This document provides an overview of recent advances in asthma treatment. It discusses novel bronchodilators such as magnesium sulfate and potassium channel openers. Immunomodulatory therapies including anti-IgE therapy and specific immunotherapy are also covered. Newer anti-inflammatory drugs that target NF-kB and MAP kinase pathways are mentioned. The document concludes by briefly discussing miscellaneous approaches like cytokine modifiers, chemokine receptor antagonists, CRTH2 antagonists, and antioxidants.
This document provides information on asthma, including its definition, types, pathophysiology, etiology, symptoms, diagnosis, and treatment. Asthma is defined as a chronic inflammatory disease of the airways characterized by variable airflow obstruction and airway hyperresponsiveness. It discusses the different types of asthma including allergic, non-allergic, cough variant, occupational, and exercise-induced asthma. Treatment involves both controller medications to reduce inflammation and reliver medications for acute symptoms. Treatment is escalated in steps based on asthma severity and control.
This document presents a case study of a family with multiple asthmatic children who experience recurrent breathing difficulties. The family has limited financial resources. The case focuses on a 2-year-old child with mild persistent asthma and nutritional deficiencies. Interventions discussed include regular medical checkups, environmental controls, medication adherence, and addressing the family's social determinants of health.
Asthma is a chronic inflammatory airway disease characterized by periods of reversible bronchospasm. Common triggers include allergens, irritants, and environmental factors. Symptoms include wheezing, coughing, chest tightness, and shortness of breath. Diagnosis involves assessing symptoms, lung function tests, and response to treatment. Management involves long-term control medications like inhaled corticosteroids and bronchodilators, as well as quick-relief medications for exacerbations. Treatment is tailored based on asthma severity and level of control.
This document provides information about asthma, including:
- Asthma is a chronic inflammatory airway disorder characterized by airway hyperresponsiveness and inflammation.
- It has both predisposing factors like atopy and causal factors such as indoor/outdoor allergens and irritants.
- Asthma severity is classified based on symptoms, nighttime symptoms, lung function tests and medication use. Treatment involves reliever and preventer medications, and patient education.
This student "cheat sheet" is designed to provide medical students with basic information regarding the diagnosis and treatment of chronic asthma. It includes Questions to Ask, what to look for on a Physical Exam, Labs to Order, and basic Treatment Plans.
These guides are particularly designed for first and second-year medical students as an introduction to ambulatory care medicine and attempts to tie in the basic pathophysiology that is high-yield for USMLE Step 1.
Any and all feedback is very welcomed.
Asthma is a chronic inflammatory disease of the airways characterized by variable airflow obstruction that is usually reversible. It affects people of all ages but predominantly early in life. The prevalence of asthma is approximately 10-12% of the population and it is both common and exacerbated by smoking. Diagnosis involves demonstrating variable airflow obstruction and its reversibility via spirometry and peak flow measurement. Management focuses on avoidance of triggers, bronchodilators for acute exacerbations, and inhaled corticosteroids for chronic control. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by airflow limitation that is not fully reversible. Risk factors include cigarette smoking and occupational exposures. Symptoms include cough, sputum production and
drugs used in bronchial asthma & COPD.pptDrxKhan16
This document discusses the pharmacology of drugs used to treat bronchial asthma and chronic obstructive pulmonary disease (COPD). It describes the pathophysiology and symptoms of these conditions. The main classes of drugs discussed are bronchodilators and anti-inflammatory agents. Bronchodilators like short-acting beta-2 agonists are used to relieve acute asthma attacks, while long-acting beta-2 agonists and antimuscarinics are used for COPD. Anti-inflammatory drugs like inhaled corticosteroids are used to prevent asthma attacks.
This document discusses asthma, including its pathogenesis, triggers, symptoms, diagnosis and classification. It notes that asthma is a chronic inflammatory airway disease characterized by reversible bronchial constriction in response to multiple stimuli. Common symptoms include dyspnea, cough and wheezing. Diagnosis involves assessing symptoms, demonstrating reversibility of airflow obstruction via spirometry, and ruling out alternative diagnoses. Asthma is classified based on severity of symptoms and lung function.
Pharmacotherapy of Asthmatic patient in hospitalAhmanurSule5
This document provides an overview of asthma, including:
1. It defines asthma as a chronic inflammatory airway disorder characterized by reversible airway obstruction.
2. Environmental triggers and allergens can cause asthma symptoms by inducing inflammation and bronchospasm.
3. Treatment involves controlling inflammation with inhaled corticosteroids and bronchodilation with inhaled beta-agonists for acute symptoms and prevention of exacerbations.
4. Proper inhaler technique and patient education are important for effective asthma management.
This document discusses chronic obstructive pulmonary disease (COPD). It defines COPD as a progressive lung disease characterized by airflow limitation that is not fully reversible. The main phenotypes of COPD are chronic bronchitis and emphysema. The document discusses the pathogenesis and risk factors of COPD, as well as the clinical presentation and complications. It provides details on diagnosing COPD through pulmonary function tests, blood tests, imaging and other evaluations. Treatment options are outlined for acute exacerbations and management of stable COPD based on disease severity. Management includes bronchodilators, corticosteroids, pulmonary rehabilitation, oxygen therapy and occasionally surgery.
Bronchial asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, chest tightness, coughing and shortness of breath. It affects over 300 million people worldwide. The inflammation is caused by immune cells and inflammatory mediators in the airways leading to swelling, mucus production and airway constriction. Symptoms include wheezing, coughing and breathlessness that are often worse at night. Diagnosis involves lung function tests showing reduced airflow and reversibility with bronchodilators. Treatment follows a stepwise approach starting with short-acting bronchodilators and adding preventive inhaled corticosteroids and long-acting bronchodilators as needed to control symptoms
The document discusses asthma, including its causes, symptoms, diagnosis, classification, and treatment. Asthma affects 7-10% of the population and is caused by inflammation of the airways. Symptoms include coughing, shortness of breath, wheezing, and chest tightness. Diagnosis involves assessing medical history, lung function tests, and checking for allergies. Asthma is classified based on severity and control. Treatment ranges from short-acting bronchodilators for mild intermittent asthma to high-dose corticosteroids for severe persistent asthma.
Bronchial asthma is a chronic inflammatory disease of the airways characterized by airflow obstruction, bronchial hyperactivity, and mucus production. It affects 334 million people worldwide and causes 250,000 deaths per year. The disease has genetic and environmental causes and can be triggered by factors like dust, pollen, smoke, and exercise. It is diagnosed based on symptoms, medical history, and pulmonary function tests. Treatment involves bronchodilators, corticosteroids, and other drugs to relieve symptoms and reduce inflammation. Lifestyle changes and avoidance of triggers can also help manage the condition.
This document provides information on bronchial asthma, including:
- Asthma is a chronic inflammatory airway disease characterized by wheezing, breathlessness, and coughing.
- It affects over 350 million people globally and causes nearly 400,000 deaths per year, most in developing countries.
- Long-term treatment involves inhaled corticosteroids to reduce inflammation. Other treatments include oral corticosteroids, leukotriene modifiers, and long-acting beta-2 agonists.
- Triggers include infections, allergens, exercise, air pollution, weather changes, drugs, stress, and smoking. Proper management is needed to prevent complications and control symptoms.
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
low birth weight presentation. Low birth weight (LBW) infant is defined as the one whose birth weight is less than 2500g irrespective of their gestational age. Premature birth and low birth weight(LBW) is still a serious problem in newborn. Causing high morbidity and mortality rate worldwide. The nursing care provide to low birth weight babies is crucial in promoting their overall health and development. Through careful assessment, diagnosis,, planning, and evaluation plays a vital role in ensuring these vulnerable infants receive the specialize care they need. In India every third of the infant weight less than 2500g.
Birth period, socioeconomical status, nutritional and intrauterine environment are the factors influencing low birth weight
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
2. Chronic inflammatory disease of airways
Increased responsiveness of tracheobronchial
tree
Multiplicity of stimuli
Episodic disease
Narrowing of airways (acutely and gradually),
relieved spontaneously or after therapy.
3. Risk Factors
(for development of asthma)
INFLAMMATION
Airway
Hyperresponsiveness Airflow Obstruction
Risk Factors Symptoms
(for exacerbations)
4. Asthma is one of the most common chronic
diseases worldwide —160 million patients suffer
from asthma
Prevalence increasing in many countries,
especially in children — 1~4% in adult, 3~5% in
children in China
A major cause of school/work absence
An overall increase in severity of asthma
increases the pool of patients at risk for death
5. Worldwide Variation in Prevalence of
Asthma Symptoms
International Study of
Asthma and Allergies in
Children (ISAAC)
Lancet 1998;351:1225
6. Environmental
Genetic factors factors
Mixed
Atopic factors Non-
asthma atopic/idiosyncratic
asthma
Early onset
Late onset
9. Gross overdistention of lungs, non-collapsible
Gelatinous plugs of exudate in bronchial
branches, down to terminal bronchioles
Hypertrophy of bronchial smooth muscle
Hyperplasia of mucosal & submucosal blood
vessels
Mucosal oedema
Thickening of basement membrane
Eosinophilic infiltrates in the bronchial walls
10. History and patterns of symptoms
Physical examination
Measurements of lung function
Measurements of allergic status to identify risk
factors
11. Recurrent episodes of wheezing
Troublesome cough at night
Cough or wheeze after exercise
Cough, wheeze or chest tightness after
exposure to airborne allergens or pollutants
Colds ―go to the chest‖ or take more than 10
days to clear
12. Lung function tests- FEV1/FVC ratio (<70%or
normal), PEFR
Bronchodilator test- reversibility (>15%
improvement in FEV1)
CXR
Sputum (thick, with eosinophils + Charcots-
Leyden crystals), blood (IgE levels,
eosinophilia)
Allergy tests- skin, inhalants, catecholamines
etc.
13. Asthma COPD
cannot be fully prevented can be prevented
can be fully controlled
cannot be fully reversed
does not progress is progressive
14. COPD and Asthma are different
diseases!
Asthma COPD
Allergic
Small airway
inflammation of
COPD narrowing
airways
& &
Asthma Bronchospasm
Hyper- (15%) &
responsiveness
Airway collapse
Bronchospasm
Maintain
Control inflammation
bronchodilatation
with ICS
with regular
Minimal bronchodilator
bronchodilator
15. History COPD Asthma
Smoker or ex- Nearly always Variable
smoker
Onset Usually > 40 Most < 30 years
years
Breathlessness Gradual and Paroxysmal
progressive
Chronic cough Common Infrequent
with sputum
18. To effectively controll asthma by…
A. Suppressing and reversing
inflammation
B. Treating bronchoconstriction
and related symptoms
19. Life-threatening medical emergencies
Treatment is often most safely undertaken in a
hospital or hospital-based emergency
department
20. Initial Assessment
History, Physical Examination, PEF or FEV1
Initial Therapy
Bronchodilators; O2 if needed
Good Response
Incomplete/Poor Response Respiratory Failure
Observe for at Add Systemic Glucocorticosteroids
least 1 hour
Good Response Poor Response
If Stable,
Discharge to Discharge Admit to Hospital Admit to ICU
Home
21. Goals of Long-term Management
Achieve and maintain control of symptoms
Prevent asthma episodes or attacks
Maintain pulmonary function as close to normal levels
as possible
Maintain normal activity levels, including exercise
Avoid adverse effects from asthma medications
Prevent development of irreversible airflow limitation
Prevent asthma mortality
22. Uncontrolled
Controlled (mild Partly controlled (moderate-
Characteristic intermittent) (mild persistent) severe
(All of the following) (Any present in any week)
persistent)
None (2 or less / More than
Daytime symptoms
week) twice / week
Limitations of 3 or more
None Any features of
activities
partly
Nocturnal controlled
symptoms / None Any asthma
awakening present in
Need for rescue / None (2 or less / More than any week
“reliever” treatment week) twice / week
< 80% predicted or
Lung function
Normal personal best (if
(PEF or FEV1)
known) on any day
Exacerbation None One or more / year 1 in any week
23. Preventers - anti-inflammatory
Relievers - short acting bronchodilators
that provide rapid relief of
symptoms
Controllers - sustained bronchodilator
action with unproven or mild
anti-inflammatory action
24. Classification of drugs used in the
maintenance treatment of asthma
PREVENTERS CONTROLLERS RELIEVERS
Anti-inflammatory Sustained broncho- For quick relief of
action to prevent dilator action but weak symptoms and use in
asthma attacks or unproven anti- acute attacks as p.r.n.
inflammatory effect dose only
Inhaled Long-acting ß2 Short-acting ß2
corticosteroids agonists agonists
Beclomethasone Salmeterol Salbutamol
Budesonide Formoterol Fenoterol
Fluticasone Methylxanthines Terbutaline
Flunisolide Hexoprenaline
Triamcinolone
Sustained-release Orciprenaline
theophyllines
Oral Anti-cholinergics
corticosteroids Leukotriene Ipratropium
Prednisone receptor Short-acting
Prednisolone antagonists** theophyllines
Methylprednisolone Montelukast
Zafirlukast
** Provisional categorisation pending further data
26. A convenient and reliable
multi-dose device
New propellant is HFA
(ozone-friendly)
Rapidly moving, short-
duration plume
Impaction of spray in
oropharynx likely
Evaporating spray feels
cold
70% of dose lodges in
pharynx and much may be
swallowed, 15 -20% in
lung
27. Remove mouthpiece
cap
Shake inhaler
(suspensions only)
Breathe out
Place actuator
mouthpiece between lips
Fire while breathing in
slowly and deeply
Continue to inhale
Hold breath (for 10 sec)
28. CRUCIAL ERRORS
Firing device at or after end of inhalation
Stopping inhalation / inhaling through nose (―cold
Freon‖ effect)
Bizarre errors (e.g. not removing mouthpiece cap)
NON-CRUCIAL ERRORS
Firing device before start of inhalation
Fast inhalation
No breath-hold / short breath-hold
Failure to shake inhaler (suspensions only)
29. Useful for small children (used with
snug-fitting face mask)
Useful in improving inhaled steroid
deposition in those with difficulty co-
ordinating firing of pMDI during or
before inhalation
Shake inhaler (suspensions only)
Insert pMDI into spacer
Breathe out
Fire while (or before) breathing in
slowly and deeply
Continue to inhale
Hold breath (for 10 sec)
Repeat with second puff
30.
31. Remove cover (device-specific)
Prepare device / load dose (device-specific)
Pierce capsule (single-dose devices only)
Breathe out gently
Place mouthpiece between lips
Inhale deeply and quickly*
Breath-hold (device-specific)
Replace cover and store in dry cool environment
32. Montelukast - Singulair
Zafirlukast - Accolate
Advantages:
• Unique mode of action
• Anti-inflammatory – no bronchodilator effect
• Very simple dosing: taken by mouth; single dose strength for children, another for
adults
• Safe
• Use:
– Add to inhaled corticosteroids
– Monotherapy in mild allergic asthma (children)
Disadvantages:
• Poor efficacy (not better than theophylline for most endpoints especially in adults
( More useful in children)
• Expensive !
33. DISADVANTAGES
ADVANTAGES Bulky, inconvenient
Easy to use correctly once Electricity supply usually needed
prepared: relaxed tidal Preparation and assembly a problem,
breathing especially for the elderly?
Convenient way of Long treatment times
delivering high doses
Patients find them Cleaning / contamination issues
reassuring Expensive
Dose control possible in Patients rely on them instead of using
sophisticated devices controller medications
No propellants needed Their use can delay patients presenting to
emergency departments and lead to
asthma deaths (false sense of security)
They are air and not oxygen-driven, so do
not correct hypoxia
34. Reasons for poor
patient adherence to treatment
Misunderstanding about need for both
long-term preventive and quick-relief
medications
Difficulty with inhaler devices
Fear of side effects or addiction
Cost of medication
Dislike of medication
35. Follow-up
At regular visits (every one to six months):
Monitor asthma control
– Review symptoms
– Measure lung function
– Assess compliance
Modify the treatment plan
– Reinforce compliance
– Adjust medications
36. Kasper et-al. Harrison’s Principles of Internal
Medicine, 16th edition: 2005; McGraw-Hill, New York,
USA: pp1508-1516
Zhiwen Zhu. Pulmonary & Critical Care Medicine, 1st Affiliated
Hospital of Sun Yat-Sen University, China